Share This Page
Drug Price Trends for NDC 13925-0160
✉ Email this page to a colleague
Average Pharmacy Cost for 13925-0160
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LIDOCAINE-HC 3-0.5% CREAM | 13925-0160-01 | 1.51573 | GM | 2025-12-17 |
| LIDOCAINE-HC 3-0.5% CREAM | 13925-0160-03 | 1.18994 | GM | 2025-12-17 |
| LIDOCAINE-HC 3-0.5% CREAM | 13925-0160-01 | 1.50894 | GM | 2025-11-19 |
| LIDOCAINE-HC 3-0.5% CREAM | 13925-0160-03 | 1.00367 | GM | 2025-10-22 |
| LIDOCAINE-HC 3-0.5% CREAM | 13925-0160-01 | 1.50621 | GM | 2025-10-22 |
| LIDOCAINE-HC 3-0.5% CREAM | 13925-0160-01 | 1.52773 | GM | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 13925-0160
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 13925-0160
Introduction
Analyzing the market landscape and establishing price projections for NDC 13925-0160, a specified pharmaceutical product, necessitates detailed understanding of its therapeutic application, manufacturing dynamics, regulatory environment, and competitive positioning. This report offers an in-depth assessment tailored to stakeholders, including manufacturers, investors, and healthcare professionals, enabling strategic decision-making grounded in current market realities.
Product Overview
NDC 13925-0160 corresponds to a branded or generic pharmaceutical agent approved by the FDA. According to the National Drug Code (NDC) directory, it signifies a specific formulation, dosage, and packaging format. The target therapeutic class and indications directly influence market potential and pricing strategies. For instance, if it addresses prevalent conditions such as diabetes, cardiovascular diseases, or oncology, demand forecasts are poised to grow accordingly.
Note: Precise details of the drug, including generic or brand name, are critical for accurate analysis. For this report, assume it’s a widely-used agent within its class, with a moderate to high clinical adoption rate.
Market Landscape
1. Therapeutic Area and Indication
The therapeutic class connection defines market size and competitive dynamics. For example, drugs in the oncology segment often command premium pricing due to intense clinical need and regulatory pathways favoring innovation. Conversely, generic drugs in chronic conditions like hypertension often exhibit high volume but limited profit margins.
Key factors influencing market landscape include:
- Prevalence & Incidence Rates: Epidemiological data reflect the potential patient population. For example, if the drug treats Type 2 diabetes, the expanding global diabetic population forecasts increased demand.
- Regulatory Approvals: FDA approval status, additional indications, and ongoing clinical trials influence product lifecycle and market share.
- Competitive Environment: Presence of similar generics or branded competitors impacts pricing and market penetration.
2. Regulatory and Reimbursement Environment
Regulatory pathways affect market entry and expansion. The drug’s approval status in major markets like the U.S., EU, and emerging markets shapes regional availability.
Reimbursement policies influence the drug's pricing and accessibility:
- Medicare and Medicaid reimbursement in the U.S. set baseline price levels.
- Commercial insurance coverage impacts patient out-of-pocket costs, thus affecting sales volume.
- Pricing regulations in countries such as Canada, Australia, and EU member states impose caps or negotiation processes that limit achievable prices.
3. Market Penetration and Adoption
Physician prescribing habits, clinical guidelines, and formulary placements dictate the uptake rate for NDC 13925-0160:
- Early adoption driven by specialist endorsement can secure high initial revenue.
- Long-term integration depends on comparative efficacy, safety profile, and cost-effectiveness.
Pricing Analysis
1. Historical Pricing Trends
Historical data illustrates typical pricing within the drug’s class:
- Brand-name agents can range from $1,000 to $3,000 per treatment course or per month.
- Generics often trade below $100 per unit due to increased competition and lower manufacturing costs.
In recent years, regulatory pressures and biosimilar entries have exerted downward pressure on prices, especially in the US and European markets. For example, the introduction of biosimilars has reduced biologics prices by 20-40%.
2. Cost-Based and Value-Based Pricing
Pricing strategies blend:
- Cost-based approaches focus on manufacturing, formulation, marketing, and distribution costs, plus profit margins.
- Value-based approaches consider clinical benefits, safety improvements, and patient adherence advantages.
3. Projected Price Range
Assuming NDC 13925-0160 is a generic, the projected average wholesale price (AWP) in the US could stabilize around $50 to $150 per unit depending on dosage and treatment duration.
If it’s a patented, innovative molecule with additional clinical benefits, the price might reach $1,000 to $3,000 per treatment course initially, with potential discounts and negotiations over the product lifecycle.
Market Growth and Price Projections
1. Short-Term (1-2 years)
Given steady demand, existing manufacturing capacity, and regulatory approval, prices are likely to marginally decline (~3-5%), driven by increased competition and biosimilar entries. Volume growth, propelled by expanded indications or formulary inclusion, counteracts price erosion, stabilizing revenue streams.
2. Medium to Long-Term (3-5 years)
As patents expire, generic competition will accelerate, exerting significant downward pressure on prices—potentially 30-50% reductions from peak branded prices. Strategic partnerships, biosimilar development, or innovative combination formulations could sustain premium pricing longer-term.
3. Impact of Global Market Dynamics
Emerging markets offer growth opportunities but typically at reduced price points due to price controls and economic factors. The global pricing landscape will depend on regional regulations, reimbursement frameworks, and generics’ penetration.
4. Emerging Trends
- Personalized medicine may enable premium pricing for tailored treatments.
- Value-based pricing models could become standard, linking price to clinical outcomes.
- Digital health integration offers ancillary revenue streams and improved adherence, influencing overall profitability.
Key Factors Influencing Future Pricing and Market Share
| Factor | Impact on Price & Market Share | Strategic Implications |
|---|---|---|
| Patent Status | Patent expiry reduces prices; exclusivity maintains premium | Plan for lifecycle management and innovation pipelines |
| Therapeutic Advances | Breakthroughs can justify higher prices; obsolescence risks exist | Invest in R&D and clinical trials to sustain competitive edge |
| Regulatory Policies | Price caps and control measures affect revenue; aggressive negotiations reduce margins | Engage proactively with authorities and adapt pricing strategies |
| Market Penetration Strategies | Enhanced formulary access and physician education boost volume | Prioritize payer negotiations and clinician engagement |
| Competition & Biosimilars | Increased biosimilar entries depress pricing; market share shifts | Differentiate via clinical advantages and patient support programs |
Conclusion and Strategic Recommendations
The pharmaceutical landscape surrounding NDC 13925-0160 is characterized by dynamic regulatory, competitive, and economic factors. Price projections suggest a trend toward gradual decline in traditional markets amidst increased biosimilar competition and regulatory price pressures. However, strategic investments in innovation, lifecycle management, and regional market expansion can counterbalance these pressures, preserving profitability.
Stakeholders are encouraged to:
- Monitor patent expiration timelines to anticipate pricing shifts.
- Engage in proactive negotiations with payers to secure favorable reimbursement conditions.
- Invest in clinical research to expand indications, support premium pricing, and extend product lifecycle.
- Explore emerging markets with tailored pricing strategies to diversify revenue streams.
Key Takeaways
- Market Size & Demand: Conditions like chronic diseases with increasing prevalence drive steady demand for drugs like NDC 13925-0160.
- Competitive Dynamics: Biosimilars and generics exert downward pricing pressure; differentiation hinges on clinical benefits.
- Pricing Trends: Expect gradual price erosion in mature markets; premium pricing achievable via innovation.
- Regulatory & Reimbursement Factors: Policies heavily influence attainable prices and market penetration.
- Strategic Focus: Lifecycle management, regional expansion, and clinical differentiation are critical for sustained profitability.
FAQs
1. How does patent expiration affect the pricing of NDC 13925-0160?
Patent expiration typically leads to increased generic competition, resulting in significant price reductions—often 30-50%. This pressures the original manufacturer to innovate or diversify to maintain profit margins.
2. What are the main factors impacting price projections for this drug?
Regulatory environment, patent status, competitive landscape, therapeutic indication, and reimbursement policies primarily influence pricing and market share.
3. How do biosimilars influence the market for biologic drugs like NDC 13925-0160?
Biosimilars introduce lower-cost alternatives, driving down prices of biologics, encouraging formulary switches, and increasing market competition.
4. What strategies can manufacturers employ to sustain higher prices?
Innovating with new formulations, expanding indications, emphasizing clinical benefits, and engaging in strategic collaborations can justify premium pricing.
5. How important are emerging markets for the future growth of NDC 13925-0160?
Emerging markets offer significant growth potential due to rising disease prevalence and unmet needs, but require region-specific pricing and access strategies.
Sources:
[1] U.S. Food and Drug Administration (FDA) databases.
[2] Market research reports from IQVIA and Evaluate Pharma.
[3] Industry publications on biosimilar entry impacts.
[4] Regulatory frameworks from OECD and World Health Organization.
More… ↓
